Single-Agent TDF Versus Combination FTC/TDF PrEP Among Heterosexual Men and Women
Background: Antiretroviral pre-exposure prophylaxis (PrEP), using daily oral tenofovir (TDF) alone or combination emtricitabine/tenofovir (FTC/TDF), has been demonstrated to be an efficacious HIV-1 prevention intervention in four clinical trials. Whether single-agent TDF PrEP has comparable efficacy to dual-agent FTC/TDF PrEP is unknown. Methodology: The Partners PrEP Study was a randomized, double-blind, placebo-controlled three-arm trial of…